POC Rapid Diagnostics Platform Leverages Graphene-Based Biosensors for Real-Time Disease Detection
|
By LabMedica International staff writers Posted on 08 Jun 2023 |

A revolutionary graphene-based technology enables testing for a broad range of indications using a variety of sample types in less than five minutes at POC, placing high-performance diagnostics directly in the hands of medical professionals.
GrapheneDx (Boston MA, USA), an in vitro diagnostics company, is focusing on improving diagnostic capability at the point of care by industrializing graphene-based biosensors for medical devices used to diagnose a variety of diseases. Known for its superior electrical properties, graphene - a single-atom, thick layer of carbon - enables the highly accurate detection of diverse biomolecules. The medical devices developed by GrapheneDx are designed to match lab-quality accuracy, yield results in less than five minutes, and be easy enough to be used in professional healthcare settings.
GrapheneDx has developed the GFET platform which demonstrates remarkable versatility in diagnosing various conditions such as sexually transmitted infections, respiratory and cardiac diseases, concussion, and more, using different sample types like stool, urine, swabs, blood, etc., with minimal or no sample preparation. Moreover, the platform has the capability to concurrently multiplex multiple analytes using a single patient sample. The first tests introduced by GrapheneDx will focus on the diagnosis of sexually transmitted infections, specifically Chlamydia and Gonorrhea, utilizing a noninvasive, easy-to-collect urine sample.
Related Links:
GrapheneDx
Latest Technology News
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Channels
Clinical Chemistry
view channel
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read more
Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read moreMolecular Diagnostics
view channel
Genetic Test Predicts Radiation Therapy Risk for Prostate Cancer Patients
External beam radiation therapy is widely used to treat localized prostate cancer, which has a five-year survival rate exceeding 99%. However, more than 20% of patients develop persistent urinary side... Read more
Genetic Test Aids Early Detection and Improved Treatment for Cancers
Lynch syndrome is a hereditary genetic condition that significantly increases the risk of several cancers, including those of the bowel and urinary tract. Urinary tract cancers—affecting the kidney, bladder,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read more
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read more
AI-Powered 3D Scanning System Speeds Cancer Screening
Cytology remains a cornerstone of cancer detection, requiring specialists to examine bodily fluids and cells under a microscope. This labor-intensive process involves inspecting up to one million cells... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







